ALK-Abelló A/S
Save
27.69B
Market cap
59.09x
Current P/E
–
Forward P/E
About
Health care
Sector
Biotechnology
Industry
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. It product portfolio include GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food.
Similar securities
Based on sector and market capitalization
Report issue